Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study to Evaluate the Safety and Efficacy of Co-administration of AGN-151586 and BOTOX® in Subjects for Treatment of Glabellar Lines (GL)

NCT06834789 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT06834789
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06834789 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study to Evaluate the Safety and Efficacy of Co-administration of AGN-151586 and BOTOX® in Subjects for Treatment of Glabellar Lines (GL)
Lead sponsor
AbbVie
Phase
Phase 1
Overall status
Completed
Start date
February 18, 2025
Completion date
November 3, 2025
Enrollment
132 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

glabellar lines